ArticleImmunoTargets and therapy2026
The Dual Mechanism of Action of CO-005 Overcomes CD20 Resistance in Diffuse Large B-Cell Lymphoma.
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Despite the clinical success of anti-CD20 monoclonal antibodies (mAbs) such as rituximab in the treatment of B-cell lymphoma, therapeutic resistance and relapse remain significant challenges, particularly in tumors with low or heterogeneous CD20 expression resulting from antigen loss or phenotypic shifts. To address this limitation, new therapeutic strategies are needed that act independently of CD20 while maintaining robust immune effector engagement. CO-005 is a humanized anti-CD47 fusion protein designed to simultaneously disrupt the CD47-SIRPα checkpoint and induce direct programmed cancer cell death (PCCD) distinct from other anti-CD47 agents. Methods: The capacity of therapeutic mAbs to induce PCCD was assessed in lymphoma cell lines by flow cytometric detection of cell death and apoptotic markers. Antibody binding, phagocytic activity, and mechanistic analyses assessed intracellular signaling events associated with PCCD were measured by flow cytometry following treatment. The antitumor activity of CO-005 was evaluated in NOD-scid IL2Rγnull (NSG) mice bearing subcutaneous lymphoma xenografts, with efficacy and survival outcomes assessed for CO-005 as monotherapy and in combination with rituximab. Results: CO-005 demonstrated potent and durable antitumor activity across multiple lymphoma xenograft models, including rituximab-resistant tumors model. CO-005 shares key mechanistic features with therapeutic anti-CD20 antibodies independent of CD20 signaling, including the induction of type III programmed cell death via receptor capping, calcium flux, reactive oxygen species generation, and actin cytoskeleton dependence, accompanied by surface calreticulin exposure. In vivo, CO-005 triggered robust intratumoral PCCD and remodelled the tumor microenvironment, characterized by increased macrophage and neutrophil infiltration, thereby enhancing innate immune activation and supporting a dual-mechanism mode of action that couples direct cancer cell killing with myeloid engagement. Conclusion: These findings position CO-005 as a mechanistically distinct and immunologically active therapeutic with the potential to overcome limitations of both CD20- and CD47-directed therapies and expand treatment options for B-cell lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.